Immunomodulating heterocyclic compounds

A method of immuno-inhibition in mammals, including humans, comprising administration to a mammal in need of such treatment an immuno-inhibititory effective dose of a compound comprising a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt or hydrate thereof:

• wherein
• R1 and R3 independently represent H;
• F;
• Cl;
• Br;
• —NO2;
• —CN;
• C1-C6 alkyl optionally substituted by F or Cl;
• or C1-C6 alkoxy optionally substituted by F;
• R4 represents a carboxylic acid group (—COOH) or an ester thereof, or —C(═O)NR6R7, —NR7C(═O)R6, —NR7C(═O)OR6, —NHC(═O)NR7R6 or —NHC(═S)NR7R6 wherein
• R6 represents H, or a radical of formula -(Alk)m-Q wherein
• m is 0 or 1
• Alk is an optionally substituted divalent straight or branched C1-C12 alkylene, or C2-C12 alkenylene, or C2-C12 alkynylene radical or a divalent C3-C12 carbocyclic radical, any of which radicals may contain one or more —O—, —S— or —N(R8)— links wherein R8 represents H or C1-C4 alkyl, C3-C4 alkenyl, C3-C4 alkynyl, or C3-C6 cycloalkyl, and
• Q represents H;
• —NR9R10 wherein R9 and R10 independently represents H;
• C1-C4 alkyl;
• C3-C4 alkenyl;
• C3-C4 alkynyl;
• C3-C6 cycloalkyl;
• an ester group;
• an optionally substituted carbocyclic or heterocyclic group;
• or R9 and R10 form a ring when taken together with the nitrogen to which they are attached, which ring is optionally substituted;
• and
• R7 represents H or C1-C6 alkyl;
• or when taken together with the atom or atoms to which they are attached R6 and R7 form an optionally substituted monocyclic heterocyclic ring having 5, 6 or 7 ring atoms;
• and
• X represents a bond or a divalent radical of formula -(Z)n-(Alk)- or -(Alk)-(Z)n- wherein Z represents —O—, —S— or —NH—, Alk is as defined in relation to R6 and n is 0 or 1.